Dermorphin

Dermorphin is a naturally occurring hepta-peptide (7 amino acids) isolated from the skin of South American frogs (e.g., Phyllomedusa sauvagei). Its potent pharmacological activity stems from its unique structure, which includes a D-alanine residue, and its high affinity for opioid receptors.

• Mu-Opioid Receptor (MOR) Agonism: Dermorphin acts as a highly potent and selective agonist at mu-opioid receptors in the central nervous system. Activation of MORs is primarily responsible for analgesia (pain relief), as well as other opioid-related effects such as respiratory depression, euphoria, and gastrointestinal motility changes.
• Enhanced Receptor Binding and Stability: The presence of D-alanine at the second position in its sequence (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is crucial for its high potency and selectivity, as it confers increased resistance to enzymatic degradation by peptidases, thereby prolonging its half-life and duration of action compared to naturally occurring L-amino acid opioid peptides.
• Modulation of Neurotransmitter Release: Like other opioid agonists, Dermorphin's binding to MORs can inhibit the release of various neurotransmitters involved in pain transmission and other neural pathways.

Its unique pharmacological profile makes Dermorphin a valuable research tool for studying opioid receptor pharmacology, the mechanisms of analgesia, and the development of novel opioid analogs with potentially altered side-effect profiles.

Dermorphin has been a subject of **preclinical and limited early-phase human research**, primarily due to its exceptional potency and selectivity for the mu-opioid receptor. Despite its compelling pharmacological profile, its clinical development has been constrained by significant safety concerns and regulatory status. Key areas of research focus include:

• Analgesia Mechanisms: Extensive preclinical research in animal models investigates its potent antinociceptive (pain-blocking) effects, often comparing its efficacy and duration of action to morphine. Studies explore its effects on various pain pathways.
• Opioid Receptor Pharmacology: Dermorphin serves as a valuable tool for understanding the structure-activity relationships of opioid peptides, receptor binding profiles, and downstream signaling events of mu-opioid receptors.
• Tolerance and Dependence Potential: Some preclinical studies have explored whether Dermorphin exhibits a slower development of tolerance or fewer withdrawal symptoms compared to traditional opioids like morphine, though findings are complex and require further investigation.
• Central Nervous System Effects: Beyond analgesia, research examines its impact on respiratory function, gastrointestinal motility, and other CNS-mediated effects in animal models.
• Biomimetic and Analog Development: Researchers study Dermorphin's unique structure to design novel synthetic analogs with improved therapeutic windows or reduced side effects.

It is critical to emphasize that while Dermorphin has shown impressive effects in research, it is an **investigational research chemical** and has not been approved by regulatory bodies (e.g., FDA, EMA) for any therapeutic use in humans or animals. Its use outside of controlled laboratory research is highly discouraged due to its potent pharmacological activity and potential for severe adverse effects, as well as its status as a prohibited substance in certain contexts (e.g., horse racing).

Dermorphin is strictly intended for **laboratory research purposes only**. It must be handled by qualified research personnel in a controlled laboratory environment, adhering to all applicable safety protocols and guidelines for potent investigational research chemicals, and strictly within the confines of a Controlled Substance license if applicable in your jurisdiction. This product is **not approved for human consumption, therapeutic use, or veterinary applications**. Its use is limited to scientific investigation and analysis. Proper laboratory safety equipment, including robust personal protective equipment (PPE), and strict procedures must be employed during its handling, storage, and experimental application. Researchers should consult relevant safety data sheets (SDS) and institutional guidelines before use, and be aware of regulations pertaining to opioid research substances.

For more detailed information on Dermorphin and its research applications, please refer to the following foundational and review scientific literature:

• Melchiorri P, Negri L. "Dermorphin: a powerful opioid peptide from amphibian skin." Nature. 1981 Apr 9;290(5806):515-6. PMID: 6166162 (Discovery and early characterization)
• Montecucci PC, et al. "Dermorphin and [D-Ala2]dermorphin: highly potent opioid peptides." J Med Chem. 1981 Dec;24(12):1423-7. PMID: 6253457 (Potency and structural aspects)
• Broccardo M, et al. "Pharmacology of dermorphin." Peptides (Fayetteville). 1982;3(6):897-900. PMID: 6292359 (Comprehensive pharmacological profile)
• Castiglione R, et al. "Receptor binding profiles of dermorphin and related peptides." Life Sci. 1981 Nov 16;29(20):2065-72. PMID: 6271960 (Receptor selectivity studies)
• Erspamer V, et al. "The opioid peptide dermorphin: structure-activity studies." Br J Pharmacol. 1981 Jun;73(2):503-6. PMID: 6264901 (Structure-activity relationship insights)
• PubChem Compound Summary: Dermorphin (CID 5485199)

*(Note: These references highlight key preclinical studies and reviews foundational to understanding Dermorphin's pharmacology. Due to its status as a potent research chemical and past misuse, caution is advised in interpreting research for non-laboratory applications.)*

This product, Dermorphin, is sold exclusively for **research and development purposes**. It is classified as a research chemical and is **not a drug, food, or cosmetic**. It has not been evaluated or approved by the FDA or any other regulatory authority for safety, efficacy, or any other use in humans or animals. By purchasing this product, the user acknowledges and agrees to comply with all applicable local, national, and international laws and regulations regarding the handling, storage, and use of research compounds, particularly those concerning potent pharmacological agents. Any use of this product for purposes other than legitimate scientific research is strictly prohibited and may lead to severe legal and health consequences.